PHASE I STUDY OF ADOPTIVE T CELL THERAPY FOLLOWING HER2-PULSED DENDRITIC CELL VACCINE AND PEPINEMAB/TRASTUZUMAB IN PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER (MBC)

被引：0
|
作者：
Han, Hyo [1 ]
Evans, Elizabeth [2 ]
Fisher, Terrence [2 ]
Soliman, Hatem [1 ]
Khong, Hung [1 ]
Soyano, Aixa [1 ]
Costa, Ricardo [1 ]
Loftus, Loretta [1 ]
Lee, Kimberley [1 ]
Armaghani, Avan [1 ]
Liu, Hien [1 ]
Locke, Frederick [1 ]
Shrewsbury, Alexandria [1 ]
Malka, Jessica [1 ]
Karyampudi, Lavakumar [1 ]
Zauderer, Maurice [2 ]
Czerniecki, Brian [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Vaccinex Inc, Rochester, NY USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0645
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
645
引用
收藏
页码：A676 / A676
页数：1
相关论文
共 50 条
  • [21] Capacitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC)
    Chan, A.
    Yamamoto, D.
    Bell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Safety of the combination of lapatinib (L) plus trastuzumab (T) in patients (pts) with HER2-Positive (+) metastatic breast cancer (MBC)
    Storniolo, A.
    Koehler, M.
    Preston, A.
    Rappold, E.
    Byrne, J.
    Stein, S.
    Ewer, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 187 - 187
  • [23] Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
    Jain, Sarika
    Shah, Ami N.
    Santa-Maria, Cesar A.
    Siziopikou, Kalliopi
    Rademaker, Alfred
    Helenowski, Irene
    Cristofanilli, Massimo
    Gradishar, William J.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (02) : 371 - 381
  • [24] A multicenter study of trastuzumab N and vinorelbine (N) as first and second line therapy for patients (pts) with HER2-positive metastatic breast cancer (HER2+ MBC).
    Franquesa, RM
    Centelles, M
    Villadiego, K
    Janáriz, J
    Arcusa, A
    Cirera, L
    Segui, M
    Saigi, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 94S - 94S
  • [25] Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
    Sarika Jain
    Ami N. Shah
    Cesar A. Santa-Maria
    Kalliopi Siziopikou
    Alfred Rademaker
    Irene Helenowski
    Massimo Cristofanilli
    William J. Gradishar
    Breast Cancer Research and Treatment, 2018, 171 : 371 - 381
  • [26] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [27] Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).
    Freixinos, V.
    Sanchez-Olle, G.
    De Mattos-Arruda, L.
    Di Cosimo, S.
    Saura, C.
    Gomez, P.
    Perez-Garcia, J. M.
    Cortes, J.
    Baselga, J.
    Bellet, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer
    Church, David N.
    Price, Chris G. A.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 557 - 570
  • [29] Phase I Study of S-1 in Combination with Trastuzumab for HER2-positive Metastatic Breast Cancer
    Nakayama, Takahiro
    Morita, Satoshi
    Takashima, Tsutomu
    Kamigaki, Shunji
    Yoshidome, Katsuhide
    Ito, Toshikazu
    Taguchi, Tetsuya
    Sakamoto, Junichi
    Noguchi, Shinzaburo
    ANTICANCER RESEARCH, 2011, 31 (09) : 3035 - 3039
  • [30] A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Chen, W.
    Savoie, J.
    Fornier, M.
    Krop, I. E.
    Winer, E. P.
    Bunnell, C.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
12345